First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX
TLX FINAL DEADLINE ALERT: Hagens Berman Alerts Telix Pharm. (TLX) Investors of Today’s Lead Plaintiff Deadline in Securities Class Action
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights